Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

21 Sept 2006

Abstract excerpt

BACKGROUND: We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH). METHODS: We conducted a double-blind, randomized, placebo-controlled, multicenter, phase 3 trial. Patients received either placebo or eculizumab intravenously; eculizumab was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Complement system in diseases
Share to Renal Diseases and Glomerulopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16990386
DOI: 10.1056/nejmoa061648

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaPMID 16990386Read ↗

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapySemantic proximity Read ↗

Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy.Semantic proximity Read ↗

Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitorSemantic proximity Read ↗

How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.Semantic proximity Read ↗

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic StrategiesSemantic proximity Read ↗

Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.Semantic proximity Read ↗

With complements: C3 inhibition in the clinicSemantic proximity Read ↗

Current status and perspectives of hematopoietic cell transplantation in patients with paroxysmal nocturnal hemoglobinuriaSemantic proximity Read ↗

Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.Semantic proximity Read ↗

Paroxysmal Nocturnal Hemoglobinuria: Biology and TreatmentSemantic proximity Read ↗

Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuriaSemantic proximity Read ↗

Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.